Finerenone in Diabetic Chronic Kidney Disease from Receptor Biology to Hyperkalemia Monitoring

Key Takeaways

• Patients with type 2 diabetes and albuminuric chronic kidney disease continue to carry a significant residual risk of kidney failure, hospitalization for heart failure, and cardiovascular death, despite maximally tolerated renin-angiotensin system blockade and sodium-glucose cotransporter 2 inhibition; nonsteroidal mineralocorticoid receptor antagonism targets a mechanistically distinct component of this residual risk.
• Mineralocorticoid receptor overactivation occurs in the tubular epithelium, podocytes, cardiomyocytes, fibroblasts, and monocyte-macrophage series; it triggers proinflammatory and profibrotic gene programs largely independent of blood pressure and circulating aldosterone concentrations. This explains how an antifibrotic agent can reduce albuminuria without acting primarily as a diuretic or antihypertensive.
• Practical dosing is based on only two variables: estimated glomerular filtration rate (eGFR) and serum potassium. Initiation requires an eGFR of at least 25 mL/min/1.73 m2 and a potassium level of no more than 5.0 mmol/L; the starting dose is 10 mg/day when the eGFR is 25 to less than 60, and 20 mg/day when the eGFR is 60 or greater, with a target dose of 20 mg/day.
• Serum potassium and eGFR should be re-evaluated four weeks after initiation and after each dose change, and thereafter at intervals determined by clinical stability. A potassium level rising above 5.5 mmol/L requires temporary discontinuation of the drug and restarting at 10 mg/day once the level falls to 5.0 mmol/L or less.
• The risk of hyperkalemia is real but manageable and rarely requires permanent drug cessation; dietary counseling, avoidance of strong CYP3A4 inhibitors, review of concomitant potassium-sparing agents, and use of potassium binders when necessary allow for the continuation of guideline-directed therapy rather than its abandonment.

Introduction and Clinical Background

Diabetic kidney disease remains the single largest cause of incident end-stage kidney disease worldwide; the disease’s natural history is determined not by glycemia but by the twin pathophysiological tracks of progressive albuminuria and left ventricular remodeling. For nearly three decades, the therapeutic architecture consisted of a single foundational pillar: inhibition of the renin-angiotensin system with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. Sodium-glucose cotransporter 2 inhibitors added a second pillar to this structure. Yet despite both therapies, the residual incidence of cardiovascular and renal events in individuals with type 2 diabetes and albuminuric chronic kidney disease remains unacceptably high; this repeatedly quantified risk gap is largely attributed to persistent mineralocorticoid receptor overactivation, which drives inflammation and fibrosis^[1].

Historical perspective is instructive here. The steroidal mineralocorticoid receptor antagonists spironolactone and eplerenone revolutionized the treatment of heart failure with reduced ejection fraction and were repeatedly shown in small-scale nephrology studies to reduce proteinuria when added to renin-angiotensin system blockade. However, they never gained widespread acceptance in chronic kidney disease because the therapeutic window narrows significantly as glomerular filtration rate declines: hyperkalemia, acute kidney injury, and—specific to spironolactone—antiandrogenic side effects have limited treatment persistence in real-world practice. This missed opportunity was rooted in prescribing inertia rather than a lack of clinical efficacy.

In parallel, an entire generation of anti-inflammatory drugs developed for diabetic kidney disease ended in failure. The direct targeted inhibition of individual inflammatory mediators yielded disappointing results, and most of these programs were terminated around 2016; the field regained momentum not with cytokine-targeting agents, but with the sodium-glucose cotransporter 2 inhibitors and nonsteroidal mineralocorticoid receptor antagonism that have transformed guidelines and standard-of-care approaches^[2]. Finerenone is the first agent in this class specifically approved for cardiorenal protection in chronic kidney disease associated with type 2 diabetes, and emerging clinical trial evidence supports its therapeutic role in heart failure with mildly reduced or preserved ejection fraction, where the pooled diabetic kidney disease clinical trial program indicated a 22% reduction in heart failure hospitalizations^[3]. The clinical question is therefore no longer whether mineralocorticoid receptor blockade is beneficial, but rather in which patient, at what dose, with what intensity of biochemical monitoring, and in what sequence relative to the other foundational pillars of therapy it should be implemented.

Molecular and Pathophysiological Mechanisms

Mineralocorticoid Receptor Distribution Beyond the Distal Nephron

The mineralocorticoid receptor is a ligand-activated nuclear transcription factor whose classic role—regulating epithelial sodium and potassium balance in the aldosterone-sensitive distal nephron—constitutes only a small part of its pathophysiological significance. It is expressed in the heart, vasculature, immune cells, and fibroblasts; receptor activation in these nonepithelial compartments regulates tissue remodeling rather than volume homeostasis, and pathological overactivation results in inflammation and fibrosis across the cardiorenal axis.^[4] Critically, receptor activation is not synonymous with high aldosterone levels. Ligand-independent activation via Rac1 signaling, glucocorticoid binding in the presence of oxidative stress, and salt-sensitive potentiation allow a full transcriptional response to occur even when circulating aldosterone levels are normal. Therefore, plasma aldosterone measurement has no role in selecting candidates for therapy.

The Cascade of Inflammation, Fibrosis, and Progression

Downstream of receptor activation, transcriptional programs converge on the nuclear factor kappa B and transforming growth factor-beta signaling pathways, triggering monocyte migration, galectin-3 expression, myofibroblast transdifferentiation, and interstitial collagen deposition. In the kidney, this manifests as podocyte injury, mesangial expansion, tubulointerstitial fibrosis, and glomerulosclerosis, while in the myocardium it presents as perivascular and interstitial fibrosis that impairs diastolic compliance. This mechanistic sequence, rather than effects on sodium balance, is the primary explanation for the efficacy of receptor antagonism in slowing progressive chronic kidney disease; indeed, this is the core argument supporting the extension of this drug class to nondiabetic kidney disease as well.^[5]

Tubular Mitochondrial Biology

Diabetic tubulopathy has emerged as a determinant of functional loss at least as important as glomerular injury. In human proximal tubule epithelial cells exposed to high glucose and in diabetic mouse kidneys, mineralocorticoid receptor activation disrupted mitochondrial dynamics and mitophagy and increased mitochondrial reactive oxygen species, whereas finerenone corrected these processes via PI3K/Akt/eNOS signaling, reducing tubular apoptosis.^[6] These are preclinical observations and should not be presented to patients as proven human data; however, they offer a coherent mechanistic explanation for how receptor blockade slows eGFR decline in a manner not explicable by its modest hemodynamic effects.

Why the Nonsteroidal Scaffold Matters

Finerenone is a bulky, nonsteroidal dihydropyridine derivative that exhibits a distinct binding mode to the receptor, creating a different coregulator recruitment profile and a different downstream gene expression pattern than spironolactone or eplerenone. Unlike spironolactone, which accumulates more densely in kidney tissue, its tissue distribution between the heart and kidney is balanced, and in rodent models, finerenone at equinatriuretic doses has demonstrated more potent anti-inflammatory and anti-fibrotic renal effects compared to eplerenone.^[4] Furthermore, it has no long-half-life active metabolites and lacks clinically significant affinity for androgen, progesterone, or glucocorticoid receptors, which removes gynecomastia and menstrual irregularities from its adverse effect profile.

Clinical Evidence and Guideline Comparison

Dose Finding: ARTS-DN

In the phase 2b ARTS-DN trial, 823 patients with diabetes and high or very high albuminuria who were already receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker were randomized to placebo or one of seven finerenone doses ranging from 1.25 to 25 mg daily for 90 days, with the primary endpoint being the urinary albumin-to-creatinine ratio.^[7] At higher doses, a dose-dependent reduction in albuminuria of approximately 20% to 40% was observed without a clinically significant increase in discontinuation rates due to hyperkalemia, and it was this exposure-response relationship that determined the 10 and 20 mg daily doses carried forward into the phase 3 trials.

FIDELIO-DKD: Renal Outcomes in Advanced Disease

The FIDELIO-DKD trial randomized 5,734 patients with type 2 diabetes to finerenone or placebo. Inclusion criteria required patients, all receiving a maximally tolerated dose of a renin-angiotensin system blocker, to have either an eGFR of 25 to less than 60 mL/min/1.73 m2 with a urinary albumin-to-creatinine ratio of 30 to less than 300 and the presence of diabetic retinopathy, or an eGFR of 25 to less than 75 with a urinary albumin-to-creatinine ratio of 300 to 5000; the primary endpoint was a composite of kidney failure, a sustained decrease of at least 40% in eGFR, or death from renal causes.^[8] Over a median follow-up of 2.6 years, the primary endpoint occurred in 17.8% of patients versus 21.1% in the placebo group (hazard ratio [HR] 0.82; 95% CI 0.73 to 0.93), corresponding to a number needed to treat (NNT) of approximately 29 for three years; the key secondary cardiovascular composite endpoint was also reduced (HR 0.86; 95% CI 0.75 to 0.99).

FIGARO-DKD: Cardiovascular Outcomes in Earlier-Stage Disease

The FIGARO-DKD trial deliberately enrolled a patient population with better-preserved filtration function and a broader range of albuminuria: patients with an eGFR of 25 to 90 and a urinary albumin-to-creatinine ratio of 30 to less than 300, or an eGFR of at least 60 with a urinary albumin-to-creatinine ratio of 300 to 5000 were included; the primary endpoint was defined as a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.^[9] The primary endpoint was met (HR 0.87; 95% CI 0.76 to 0.98); the fact that this benefit was driven predominantly by a reduction in first hospitalizations for heart failure rather than by atherothrombotic events has repositioned finerenone as a heart failure prevention agent in this population.

FIDELITY: The Prespecified Pooled Analysis

The FIDELITY pooled analysis, which aggregated individual patient-level data, combined both trials and included 13,026 patients followed for a median of 3.0 years (interquartile range 2.3 to 3.8); in this analysis, the composite cardiovascular outcome occurred in 825 (12.7%) patients receiving finerenone compared with 939 (14.4%) receiving placebo.^[10] The corresponding hazard ratio (HR) was 0.86 (95% CI 0.78 to 0.95) for the cardiovascular composite and 0.77 (95% CI 0.67 to 0.88) for the renal composite of kidney failure, a sustained decrease in eGFR of at least 57%, or death from renal causes. Effects were consistent across different eGFR and albuminuria strata, supporting the concept that albuminuria, rather than filtration rate, is the primary indication for treatment.

Interaction with Sodium-Glucose Cotransporter 2 Inhibition

In a prespecified FIDELITY subgroup analysis, 877 patients (6.7%) were using a sodium-glucose cotransporter 2 inhibitor at baseline, and 1113 patients (8.5%) initiated this therapy during follow-up; the hazard ratios (HR) for the composite cardiovascular endpoint were 0.87 (95% CI 0.79 to 0.96) in those without background inhibitor therapy and 0.67 (95% CI 0.42 to 1.07) in those with it, with no heterogeneity detected for treatment effect.^[11] The wide confidence interval reflects the small number of patients rather than an absence of benefit, and pooled trial observations suggest that hyperkalemia risk may be attenuated when the two drug classes are co-administered. Actuarial modeling using data from two sodium-glucose cotransporter 2 inhibitor trials, both finerenone trials, and eight glucagon-like peptide-1 receptor agonist trials has projected that combination therapy provides several additional years of survival free from kidney failure and cardiovascular events compared with conventional care.^[12]

Initiating Combination Therapy and Its Place in Network Meta-Analyses

The CONFIDENCE trial tested simultaneous rather than sequential initiation. Participants with type 2 diabetes on a renin-angiotensin system inhibitor with an eGFR of 30 to 90 and a urinary albumin-to-creatinine ratio of 100 to 5000 were randomized to finerenone 10 or 20 mg/day, empagliflozin 10 mg/day, or a combination of both; the primary endpoint was the relative change in the log-transformed urinary albumin-to-creatinine ratio at day 180 (baseline median ratio 579).^[13] Dual therapy was markedly superior to either monotherapy, providing an approximately 50% reduction in albuminuria, consistent with additive, mechanistically complementary effects. At the level of evidence synthesis, a living network meta-analysis including 869 trials and 493,168 participants established with moderate to high certainty that finerenone provides cardiovascular and renal benefit in patients with established chronic kidney disease^[14]; a previous version of this analysis, encompassing 816 trials and 471,038 patients, was the first to formally incorporate nonsteroidal mineralocorticoid receptor antagonists into the comparative hierarchy of type 2 diabetes pharmacotherapy.^[15] Current kidney and diabetes guidelines are aligned with this, positioning finerenone as an agent to be added to, not replace, renin-angiotensin system blockade and sodium-glucose cotransporter 2 inhibition in patients with persistent albuminuria.

Practical Implications and Safety Profile

Patient Selection and Initial Clinical Workflow

The screening process is quite straightforward, relying on two laboratory parameters and one urine test. First, the degree of albuminuria should be determined by a spot urine albumin-to-creatinine ratio; a value of 30 mg/g or greater, confirmed with a second sample, establishes the indication in a patient with type 2 diabetes. Second, the eGFR level must be assessed: The threshold for initiating therapy is an eGFR of 25 mL/min/1.73 m² or higher; initiation is not recommended below this value, whereas treatment that has already been started can be continued, even with declining filtration, until dialysis is required. Third, serum potassium must be measured: The value must be 5.0 mmol/L or lower to begin therapy. Before prescribing, it is essential to ensure the patient is on the maximum licensed and tolerated dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; the patient’s medication list should be reviewed for potassium supplements, trimethoprim, potassium-sparing diuretics, and steroidal mineralocorticoid receptor antagonists, which should absolutely not be co-prescribed.

Dosing and Titration

The starting dose is 10 mg once daily for an eGFR of 30 to <60 mL/min/1.73 m² and 20 mg once daily for an eGFR of 60 or greater; the target dose is 20 mg daily. At the four-week reassessment, if serum potassium is 4.8 mmol/L or lower and the eGFR has not declined by more than 30% from baseline, it is appropriate to increase (up-titrate) the dose from 10 mg to 20 mg. If the potassium level is between 4.9 and 5.5 mmol/L, maintaining the current dose is a rational approach. Its pharmacokinetic profile allows for flexibility: Bioavailability is 43.5%, with rapid and near-complete absorption; the half-life is 2 to 3 hours at doses up to 20 mg; elimination occurs via conversion to inactive metabolites by CYP3A4 (90%) and CYP2C8 (10%). Moderate or severe renal impairment or moderate hepatic impairment increases exposure by less than 40%; as the starting dose is already determined by the eGFR level, this does not in itself require an additional dose adjustment^[16]. The tablets can be taken with or without food. Strong CYP3A4 inhibitors, including itraconazole, ketoconazole, clarithromycin, ritonavir, and cobicistat, are contraindicated; grapefruit juice should be avoided; moderate inhibitors such as erythromycin, verapamil, and diltiazem require closer potassium monitoring; while strong inducers like rifampin, carbamazepine, phenytoin, and St. John’s wort should not be combined, as they significantly reduce drug exposure. Severe hepatic impairment (Child-Pugh C) and known adrenal insufficiency are other contraindications.

Hyperkalemia: Incidence, Predictors, and Clinical Approach

In the FIDELIO-DKD safety analysis, where hyperkalemia was defined as mild for a serum potassium >5.5 mmol/L and moderate for >6.0 mmol/L; mild hyperkalemia was observed in 597 of 2785 patients (21.4%) treated with finerenone and in 256 of 2775 patients (9.2%) in the placebo group over a median follow-up of 2.6 years, and the study protocol mandated temporary discontinuation of the drug until potassium fell to 5.0 mmol/L or below, followed by reinitiation at a dose of 10 mg daily^[17]. The rate of permanent drug discontinuation due to hyperkalemia remained around 2%, and hyperkalemia-related hospitalizations were well below 1.5%. The strongest predictors were identified as higher baseline serum potassium, lower baseline eGFR, and a short-term increase in potassium following treatment initiation; these factors, when considered together, identify the patient population requiring more frequent monitoring intervals.

Monitoring Schedule and Risk Mitigation Strategies

Serum potassium and eGFR should be measured four weeks after initiating therapy, four weeks after any dose increase, and following any intercurrent illness, addition of an interacting medication, or change in the diuretic regimen. Subsequently, for stable patients with an eGFR >45 and potassium <4.8 mmol/L, measurement every three months is sufficient, whereas patients with an eGFR between 25 and 45 require re-evaluation every one to two months. A moderate acute decline (dip) in eGFR of up to 15% within the first month is hemodynamic in origin, is an expected finding, and does not constitute an indication for treatment discontinuation. The reflexive practice of immediately reducing or stopping renin-angiotensin-aldosterone system inhibitors and mineralocorticoid receptor antagonists upon the first detection of hyperkalemia has been shown to lead to suboptimal patient management; indeed, approximately half of these patients experience two or more hyperkalemia recurrences per year. Current cardiovascular and nephrology guidelines increasingly support alternative strategies, including novel potassium binders, that allow for the continuation of these prognostically beneficial therapies^[18]. Ancillary measures in clinical practice include counseling on dietary potassium restriction, correction of metabolic acidosis, avoidance of nonsteroidal anti-inflammatory drugs, and use of a thiazide or loop diuretic when volume status permits.

Future Perspectives and Open Questions

Several critical questions remain to be fully elucidated. The first of these is the sequencing of therapies. CONFIDENCE, a phase 2 trial that has completed enrollment in adults with type 2 diabetes, an eGFR of 30 to 90 mL/min/1.73 m², and a urine albumin-to-creatinine ratio of at least 100 mg/g, was designed to test whether early initiation of a finerenone and empagliflozin combination is superior to either agent alone in its effect on albuminuria over a six-month period^[19]. The trial’s three-arm, double-dummy controlled design with 807 participants and a follow-up of 7.5 to 8.5 months is explicitly powered for a surrogate endpoint rather than a hard endpoint^[20]. Albuminuria is a well-validated but imperfect surrogate parameter, and no adequately powered clinical trial has yet demonstrated that simultaneous initiation of all therapeutic pillars provides superior hard outcomes compared with rapid sequential titration.

The second question concerns populations excluded from the pivotal clinical program: those with non-diabetic chronic kidney disease, patients with an eGFR below 25, kidney transplant recipients, and individuals with type 1 diabetes. The mechanistic argument that mineralocorticoid receptor-mediated inflammation and fibrosis drive disease progression irrespective of diabetes status is quite strong, and dedicated studies focusing on non-diabetic disease groups are ongoing^[5]. Until the results of these trials are reported, generalizing the current data to these groups remains a matter of inference rather than evidence.

Third, the relationship between finerenone and incretin-based therapies needs clarification. Although combination modeling predicts a significant cumulative lifetime benefit, glucagon-like peptide-1 receptor agonists themselves reduce albuminuria and renal endpoints; thus, it is not yet known whether the effect of this triple-drug combination on fibrotic remodeling is truly additive or partially redundant. Fourth, the class-level question remains open: whether other nonsteroidal antagonists or aldosterone synthase inhibitors, which reduce ligand availability rather than blocking the receptor, will offer a wider therapeutic index in patients with advanced kidney disease awaits investigation.

Finally, clinical implementation and adherence constitute the most fundamental practical limitation. The current evidence base is built on study populations with protocolized potassium management and near-universal use of maximally tolerated renin-angiotensin system blockade, conditions that are not perfectly replicated in routine clinical practice. The clinical uptake of this drug class in heart failure with preserved ejection fraction and chronic kidney disease has been slow; the rate-limiting step here is clinician apprehension about hyperkalemia rather than any deficiency in the outcomes data. Closing this gap will depend less on the development of new molecules and more on integrating structured potassium monitoring protocols into routine nephrology, cardiology, and primary care workflows.

References

1. González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med. 2023;55(1):502-513. doi:10.1080/07853890.2023.2171110. PubMed
2. Rayego-Mateos S, Rodrigues-Diez RR, Fernandez-Fernandez B, Mora-Fernández C, Marchant V, Donate-Correa J, et al. Targeting inflammation to treat diabetic kidney disease: the road to 2030. Kidney Int. 2023;103(2):282-296. doi:10.1016/j.kint.2022.10.030. PubMed
3. Khullar D, Gupta AK, Singh K. Finerenone: Will It Be a Game-changer?. Card Fail Rev. 2024;10:e19. doi:10.15420/cfr.2024.11. PubMed
4. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-161. doi:10.1093/eurheartj/ehaa736. PubMed
5. Epstein M, Kovesdy CP, Clase CM, Sood MM, Pecoits-Filho R. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms. Am J Kidney Dis. 2022;80(5):658-666. doi:10.1053/j.ajkd.2022.04.016. PubMed
6. Yao L, Liang X, Liu Y, Li B, Hong M, Wang X, et al. Non-steroidal mineralocorticoid receptor antagonist finerenone ameliorates mitochondrial dysfunction via PI3K/Akt/eNOS signaling pathway in diabetic tubulopathy. Redox Biol. 2023;68:102946. doi:10.1016/j.redox.2023.102946. PubMed
7. Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015;314(9):884-94. doi:10.1001/jama.2015.10081. PubMed
8. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845. PubMed
9. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956. PubMed
10. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-484. doi:10.1093/eurheartj/ehab777. PubMed
11. Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, et al. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Diabetes Care. 2022;45(12):2991-2998. doi:10.2337/dc22-0294. PubMed
12. Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024;149(6):450-462. doi:10.1161/CIRCULATIONAHA.123.067584. PubMed
13. Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533-543. doi:10.1056/NEJMoa2410659. PubMed
14. Nong K, Jeppesen BT, Shi Q, Agoritsas T, Guyatt GH, White H, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. 2025;390:e083039. doi:10.1136/bmj-2024-083039. PubMed
15. Shi Q, Nong K, Vandvik PO, Guyatt GH, Schnell O, Rydén L, et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2023;381:e074068. doi:10.1136/bmj-2022-074068. PubMed
16. Heinig R, Eissing T. The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone. Clin Pharmacokinet. 2023;62(12):1673-1693. doi:10.1007/s40262-023-01312-9. PubMed
17. Agarwal R, Joseph A, Anker SD, Filippatos G, Rossing P, Ruilope LM, et al. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. J Am Soc Nephrol. 2022;33(1):225-237. doi:10.1681/ASN.2021070942. PubMed
18. Masi S, Dalpiaz H, Piludu S, Piani F, Fiorini G, Borghi C. New strategies for the treatment of hyperkalemia. Eur J Intern Med. 2025;132:18-26. doi:10.1016/j.ejim.2024.10.016. PubMed
19. Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics. Nephrol Dial Transplant. 2025;40(8):1559-1569. doi:10.1093/ndt/gfaf022. PubMed
20. Green JB, Mottl AK, Bakris G, Heerspink HJL, Mann JFE, McGill JB, et al. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). Nephrol Dial Transplant. 2023;38(4):894-903. doi:10.1093/ndt/gfac198. PubMed

Share this article

LinkedIn X Facebook WhatsApp Copy Link